Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
10.96
+0.19 (1.76%)
Nov 4, 2024, 4:00 PM EST - Market closed

Company Description

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.

The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.

Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot–Marie–Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A.

The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Addex Therapeutics Ltd
Addex Therapeutics logo
Country Switzerland
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Timothy Dyer

Contact Details

Address:
Chemin des Mines, 9
Geneva, 1202
Switzerland
Phone 41 22 884 1555
Website addextherapeutics.com

Stock Details

Ticker Symbol ADXN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency CHF
CIK Code 0001574232
CUSIP Number 00654J107
ISIN Number US00654J2069
SIC Code 2834

Key Executives

Name Position
Timothy Mark Dyer Co-Founder, Chief Executive Officer and Director
Dr. Roger G. Mills M.D. Chief Medical Officer and Director
Lénaic Teyssédou Head of Finance
Dr. Mikhail Kalinichev Ph.D. Head of Translational Science

Latest SEC Filings

Date Type Title
Sep 30, 2024 6-K Report of foreign issuer
Sep 19, 2024 6-K Report of foreign issuer
Aug 27, 2024 6-K Report of foreign issuer
Aug 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Aug 5, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Jul 22, 2024 6-K Report of foreign issuer
Jul 15, 2024 6-K Report of foreign issuer
Jul 1, 2024 6-K Report of foreign issuer
Jun 6, 2024 6-K Report of foreign issuer
Jun 5, 2024 6-K Report of foreign issuer